Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies

Current Neuropharmacology

Volumn 8, Issue 3, 2010, Pages 1570-1159

  Fitzner, Dirk ^a,b   Simons, Mikael ^a,b  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Chronic progression; Inflammation; Multiple sclerosis; Neurodegeneration; Treatment

Indexed keywords

4 AMINOPYRIDINE; ABT 874; ALEMTUZUMAB; ANTIBODY; AUTOANTIGEN; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; CLADRIBINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DIRUCOTIDE; ERYTHROPOIETIN; FINGOLIMOD; IDEBENONE; IMMUNOGLOBULIN; INOSINE; INTERFERON BETA SERINE; LAMOTRIGINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NITRIC OXIDE; RITUXIMAB; SIMVASTATIN; SUNPHENON; TACROLIMUS; TERIFLUNOMIDE; TREOSULFAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; AXONAL INJURY; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; RELAPSE; VIRUS INFECTION;

EID: 78549294190     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015910792246218     Document Type: Article

References (128)

1. Noseworthy, J.H., Lucchinetti, C., Rodriguez, M., Weinshenker, B.G. Multiple sclerosis. N. Engl. J. Med., 2000, 343, 938-952.
2. Vukusic, S., Confavreux, C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr. Opin. Neurol., 2007, 20, 269-274.
3. Miller, D.H., Leary, S.M. Primary-progressive multiple sclerosis. Lancet Neurol., 2007, 6, 903-912.
4. Polman, C.H., Reingold, S.C., Edan, G., Filippi, M., Hartung, H.P., Kappos, L., Lublin, F.D., Metz, L.M., McFarland, H.F., O'Connor, P.W., Sandberg-Wollheim, M., Thompson, A.J., Weinshenker, B.G., Wolinsky, J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann. Neurol., 2005, 58, 840-846.
5. Confavreux, C., Vukusic, S. Natural history of multiple sclerosis: a unifying concept. Brain, 2006, 129, 606-616.
6. Confavreux, C., Vukusic, S., Moreau, T., Adeleine, P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med., 2000, 343, 1430-1438.
7. McFarland, H.F., Martin, R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol., 2007, 8, 913-919.
8. Steinman, L., Martin, R., Bernard, C., Conlon, P., Oksenberg, J.R. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev. Neurosci., 2002, 25, 491-505.
9. Weiner, H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann. Neurol., 2009, 65, 239-248.
10. Trapp, B.D., Nave, K.A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci., 2008, 31, 247-269.
11. Stadelmann, C., Albert, M., Wegner, C., Bruck, W. Cortical pathology in multiple sclerosis. Curr. Opin. Neurol., 2008, 21, 229-234.
12. Miller, D.H. Biomarkers and surrogate outcomes in neurode-generative disease: lessons from multiple sclerosis. NeuroRx, 2004, 1, 284-294.
13. Katz, D., Taubenberger, J.K., Cannella, B., McFarlin, D.E., Raine, C.S., McFarland, H.F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann. Neurol., 1993, 34, 661-669.
14. Bruck, W., Bitsch, A., Kolenda, H., Bruck, Y., Stiefel, M., Lassmann, H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol., 1997, 42, 783-793.
15. Thompson, A.J., Kermode, A.G., MacManus, D.G., Kendall, B.E., Kingsley, D.P., Moseley, I.F., McDonald, W.I. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ, 1990, 300, 631-634.
16. Kappos, L., Moeri, D., Radue, E.W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C.R., Weiner, H.L., Gasperini, C., Filippi, M. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet, 1999, 353, 964-969.
17. Brex, P.A., Ciccarelli, O., O'Riordan, J.I., Sailer, M., Thompson, A.J., Miller, D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med., 2002, 346, 158-164.
18. Simon, J.H., Jacobs, L.D., Campion, M.K., Rudick, R.A., Cookfair, D.L., Herndon, R.M., Richert, J.R., Salazar, A.M., Fischer, J.S., Goodkin, D.E., Simonian, N., Lajaunie, M., Miller, D.E., Wende, K., Martens-Davidson, A., Kinkel, R.P., Munschauer, F.E., 3rd, Brownscheidle, C.M. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology, 1999, 53, 139-148.
19. Kalkers, N.F., Bergers, E., Castelijns, J.A., van Walderveen, M.A., Bot, J.C., Ader, H.J., Polman, C.H., Barkhof, F. Optimizing the association between disability and biological markers in MS. Neurology, 2001, 57, 1253-1258.
20. Fu, L., Matthews, P.M., De Stefano, N., Worsley, K.J., Narayanan, S., Francis, G.S., Antel, J.P., Wolfson, C., Arnold, D.L. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain, 1998, 121 (Pt 1), 103-113.
21. Davie, C.A., Barker, G.J., Thompson, A.J., Tofts, P.S., McDonald, W.I., Miller, D.H. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, 1997, 63, 736-742.
22. Bjartmar, C., Kidd, G., Mork, S., Rudick, R., Trapp, B.D. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol., 2000, 48, 893-901.
23. Eikelenboom, M.J., Petzold, A., Lazeron, R.H., Silber, E., Sharief, M., Thompson, E.J., Barkhof, F., Giovannoni, G., Polman, C.H., Uitdehaag, B.M. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology, 2003, 60, 219-223.
24. Petzold, A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci., 2005, 233, 183-198.
25. Oksenberg, J.R., Baranzini, S.E., Sawcer, S., Hauser, S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet., 2008, 9, 516-526.
26. De Jager, P.L., Jia, X., Wang, J., de Bakker, P.I., Ottoboni, L., Aggarwal, N.T., Piccio, L., Raychaudhuri, S., Tran, D., Aubin, C., Briskin, R., Romano, S., Baranzini, S.E., McCauley, J.L., Pericak-Vance, M.A., Haines, J.L., Gibson, R.A., Naeglin, Y., Uitdehaag, B., Matthews, P.M., Kappos, L., Polman, C., McArdle, W.L., Strachan, D.P., Evans, D., Cross, A.H., Daly, M.J., Compston, A., Sawcer, S.J., Weiner, H.L., Hauser, S.L., Hafler, D.A., Oksenberg, J.R. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet., 2009, 41, 776-782.
27. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet., 2009, 41, 824-828.
28. Ferguson, B., Matyszak, M.K., Esiri, M.M., Perry, V.H. Axonal damage in acute multiple sclerosis lesions. Brain, 1997, 120(Pt 3), 393-399.
29. Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R., Mork, S., Bo, L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med., 1998, 338, 278-285.
30. Kornek, B., Storch, M.K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., Lassmann, H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol., 2000, 157, 267-276.
31. de Waegh, S.M., Lee, V.M., Brady, S.T. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell, 1992, 68, 451-463.
32. Schneider, A., Araujo, G.W., Trajkovic, K., Herrmann, M.M., Merkler, D., Mandelkow, E.M., Weissert, R., Simons, M. Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis. J. Biol. Chem., 2004, 279, 55833-55839.
33. Anderson, J.M., Patani, R., Reynolds, R., Nicholas, R., Compston, A., Spillantini, M.G., Chandran, S. Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. Acta Neuropathol., 2009, 117, 583-589.
34. Smerjac, S.M., Bizzozero, O.A. Cytoskeletal protein carbonylation and degradation in experimental autoimmune encephalomyelitis. J. Neurochem., 2008, 105, 763-772.
35. Neumann, H. Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr. Opin. Neurol., 2003, 16, 267-273.
36. Kuhlmann, T., Lingfeld, G., Bitsch, A., Schuchardt, J., Bruck, W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time 10.1093/brain/awf235. Brain, 2002, 125, 2202-2212.
37. Frischer, J.M., Bramow, S., Dal-Bianco, A., Lucchinetti, C.F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P.S., Lassmann, H. The relation between inflammation and neurode-generation in multiple sclerosis brains. Brain, 2009, 132, 1175-1189.
38. Chard, D.T., Griffin, C.M., Parker, G.J., Kapoor, R., Thompson, A.J., Miller, D.H. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain, 2002, 125, 327-337.
39. Neumann, H., Schmidt, H., Cavalie, A., Jenne, D., Wekerle, H. Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. J. Exp. Med., 1997, 185, 305-316.
40. Redwine, J.M., Buchmeier, M.J., Evans, C.F. In vivo expression of major histocompatibility complex molecules on oligodendrocytes and neurons during viral infection. Am. J.Pathol., 2001, 159, 1219-1224.
41. Medana, I., Martinic, M.A., Wekerle, H., Neumann, H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol., 2001, 159, 809-815.
42. Friese, M.A., Fugger, L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain, 2005, 128, 1747-1763.
43. Rivera-Quinones, C., McGavern, D., Schmelzer, J.D., Hunter, S.F., Low, P.A., Rodriguez, M. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat. Med., 1998, 4, 187-193.
44. Hanisch, U.K., Kettenmann, H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci., 2007, 10, 1387-1394.
45. Smith, K.J., Lassmann, H. The role of nitric oxide in multiple sclerosis. Lancet Neurol., 2002, 1, 232-241.
46. Renganathan, M., Cummins, T.R., Waxman, S.G. Nitric oxide blocks fast, slow, and persistent Na+ channels in C-type DRG neurons by S-nitrosylation. J. Neurophysiol., 2002, 87, 761-775.
47. Stagi, M., Dittrich, P.S., Frank, N., Iliev, A.I., Schwille, P., Neumann, H. Breakdown of axonal synaptic vesicle precursor transport by microglial nitric oxide. J. Neurosci., 2005, 25, 352-362.
48. Bo, L., Dawson, T.M., Wesselingh, S., Mork, S., Choi, S., Kong, P.A., Hanley, D., Trapp, B.D. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol., 1994, 36, 778-786.
49. Liu, J.S., Zhao, M.L., Brosnan, C.F., Lee, S.C. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol., 2001, 158, 2057-2066.
50. Pitt, D., Werner, P., Raine, C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med., 2000, 6, 67-70.
51. Centonze, D., Muzio, L., Rossi, S., Cavasinni, F., De Chiara, V., Bergami, A., Musella, A., D'Amelio, M., Cavallucci, V., Martorana, A., Bergamaschi, A., Cencioni, M.T., Diamantini, A., Butti, E., Comi, G., Bernardi, G., Cecconi, F., Battistini, L., Furlan, R., Martino, G. Inflammation Triggers Synaptic Alteration and Degeneration in Experimental Autoimmune Encephalomyelitis. J. Neurosci., 2009, 29, 3442-3452.
52. Smith, T., Groom, A., Zhu, B., Turski, L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med., 2000, 6, 62-66.
53. Salter, M.G., Fern, R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature, 2005, 438, 1167-1171.
54. Karadottir, R., Cavelier, P., Bergersen, L.H., Attwell, D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature, 2005, 438, 1162-1166.
55. Mathey, E.K., Derfuss, T., Storch, M.K., Williams, K.R., Hales, K., Woolley, D.R., Al-Hayani, A., Davies, S.N., Rasband, M.N., Olsson, T., Moldenhauer, A., Velhin, S., Hohlfeld, R., Meinl, E., Linington, C. Neurofascin as a novel target for autoantibodymediated axonal injury. J. Exp. Med., 2007, 204, 2363-2372.
56. Derfuss, T., Parikh, K., Velhin, S., Braun, M., Mathey, E., Krumbholz, M., Kumpfel, T., Moldenhauer, A., Rader, C., Sonderegger, P., Pollmann, W., Tiefenthaller, C., Bauer, J., Lassmann, H., Wekerle, H., Karagogeos, D., Hohlfeld, R., Linington, C., Meinl, E. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc. Natl. Acad. Sci. USA, 2009, 106, 8302-8307.
57. Salvetti, M., Giovannoni, G., Aloisi, F. Epstein-Barr virus and multiple sclerosis. Curr. Opin. Neurol., 2009, 22, 201-206.
58. Dolei, A., Perron, H. The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: a biological interface between virology, genetics, and immunology in human physiology and disease. J. Neurovirol., 2009, 15, 4-13.
59. Mahad, D.J., Ziabreva, I., Campbell, G., Lax, N., White, K., Hanson, P.S., Lassmann, H., Turnbull, D.M. Mitochondrial changes within axons in multiple sclerosis. Brain, 2009, 132, 1161-1174.
60. Witte, M.E., Bo, L., Rodenburg, R.J., Belien, J.A., Musters, R., Hazes, T., Wintjes, L.T., Smeitink, J.A., Geurts, J.J., De Vries, H.E., van der Valk, P., van Horssen, J. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J. Pathol., 2009, 219, 193-204.
61. Su, K.G., Banker, G., Bourdette, D., Forte, M. Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr. Neurol. Neurosci. Rep., 2009, 9, 411-417.
62. Lassmann, H., Bruck, W., Lucchinetti, C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol., 2007, 17, 210-218.
63. Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol., 2004, 14, 164-174.
64. Bo, L., Vedeler, C.A., Nyland, H.I., Trapp, B.D., Mork, S.J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol., 2003, 62, 723-732.
65. Aloisi, F., Columba-Cabezas, S., Franciotta, D., Rosicarelli, B., Magliozzi, R., Reynolds, R., Ambrosini, E., Coccia, E., Salvetti, M., Serafini, B. Lymphoid chemokines in chronic neuroinflammation. J. Neuroimmunol. Chemokines Chemokine Recept. Nervous Syst., 2008, 198, 106-112.
66. Kidd, D., Barkhof, F., McConnell, R., Algra, P.R., Allen, I.V., Revesz, T. Cortical lesions in multiple sclerosis. Brain, 1999, 122 (Pt 1), 17-26.
67. Peterson, J.W., Bo, L., Mork, S., Chang, A., Trapp, B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol., 2001, 50, 389-400.
68. Kutzelnigg, A., Lucchinetti, C.F., Stadelmann, C., Bruck, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J.E., Lassmann, H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain, 2005, 128, 2705-2712.
69. Karni, A., Abraham, M., Monsonego, A., Cai, G., Freeman, G.J., Hafler, D., Khoury, S.J., Weiner, H.L. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol., 2006, 177, 4196-4202.
70. Roach, A., Boylan, K., Horvath, S., Prusiner, S.B., Hood, L.E. Characterization of cloned cDNA representing rat myelin basic protein: absence of expression in brain of shiverer mutant mice. Cell, 1983, 34, 799-806.
71. Kirkpatrick, L.L., Witt, A.S., Payne, H.R., Shine, H.D., Brady, S.T. Changes in microtubule stability and density in myelin-deficient shiverer mouse CNS axons. J. Neurosci., 2001, 21, 2288-2297.
72. Nave, K.A., Trapp, B.D. Axon-glial signaling and the glial support of axon function. Annu. Rev. Neurosci., 2008, 31, 535-561.
73. Simons, M., Trajkovic, K. Neuron-glia communication in the control of oligodendrocyte function and myelin biogenesis. J. Cell Sci., 2006, 119, 4381-4389.
74. Lappe-Siefke, C., Goebbels, S., Gravel, M., Nicksch, E., Lee, J., Braun, P.E., Griffiths, I.R., Nave, K.A. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet., 2003, 33, 366-374.
75. Griffiths, I., Klugmann, M., Anderson, T., Yool, D., Thomson, C., Schwab, M.H., Schneider, A., Zimmermann, F., McCulloch, M., Nadon, N., Nave, K.A. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science, 1998, 280, 1610-1613.
76. Li, C., Tropak, M.B., Gerlai, R., Clapoff, S., Abramow-Newerly, W., Trapp, B., Peterson, A., Roder, J. Myelination in the absence of myelin-associated glycoprotein. Nature, 1994, 369, 747-750.
77. Salzer, J.L. Polarized domains of myelinated axons. Neuron, 2003,40, 297-318.
78. Peles, E., Salzer, J.L. Molecular domains of myelinated axons. Curr. Opin. Neurobiol., 2000, 10, 558-565.
79. Waxman, S.G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat. Clin. Pract. Neurol., 2008, 4, 159-169.
80. Black, J.A., Felts, P., Smith, K.J., Kocsis, J.D., Waxman, S.G. Distribution of sodium channels in chronically demyelinated spinal cord axons: immunoultrastructural localization and electro-physiological observations. Brain Res., 1997, 761, 1.
81. Felts, P.A., Baker, T.A., Smith, K.J. Conduction in segmentally demyelinated mammalian central axons. J. Neurosci., 1997, 17, 7267-7277.
82. Bostock, H., Sears, T.A. The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination. J. Physiol., 1978, 280, 273-301.
83. Stys, P.K., Waxman, S.G., Ransom, B.R. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J. Neurosci., 1992, 12, 430-439.
84. Wiendl, H., Hohlfeld, R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology, 2009, 72, 1008-1015.
85. Leary, S.M., Thompson, A.J. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs, 2005, 19, 369-376.
86. Wolinsky, J.S., Narayana, P.A., O'Connor, P., Coyle, P.K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann.Neurol., 2007, 61, 14-24.
87. Leary, S.M., Miller, D.H., Stevenson, V.L., Brex, P.A., Chard, D.T., Thompson, A.J. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology, 2003, 60, 44-51.
88. Montalban, X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult. Scler., 2004, 10(Suppl 1), S62; discussion 62-64.
89. Montalban, X., Sastre-Garriga, J., Tintore, M., Brieva, L., Aymerich, F.X., Rio, J., Porcel, J., Borras, C., Nos, C., Rovira, A. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult. Scler., 2009, 15, 1195-1205.
90. Stuve, O., Kita, M., Pelletier, D., Fox, R.J., Stone, J., Goodkin, D.E., Zamvil, S.S. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult. Scler., 2004, 10, S58-61.
91. The CAMMS223 Trial Investigators Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis 10.1056/NEJMoa0802670. N. Engl. J. Med., 2008, 359, 1786-1801.
92. Coles, A.J., Cox, A., Le Page, E., Jones, J., Trip, S.A., Deans, J., Seaman, S., Miller, D.H., Hale, G., Waldmann, H., Compston, D.A. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol., 2006, 253, 98-108.
93. Rice, G.P., Filippi, M., Comi, G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology, 2000, 54, 1145-1155.
94. Group S.S. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology, 2001, 56, 1496-1504.
95. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet, 1998, 352, 1491-1497.
96. Kappos, L., Weinshenker, B., Pozzilli, C., Thompson, A.J., Dahlke, F., Beckmann, K., Polman, C., McFarland, H. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology, 2004, 63, 1779-1787.
97. Hartung, H.P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S.P., Krapf, H., Zwingers, T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet, 2002, 360, 2018-2025.
98. Debouverie, M., Vandenberghe, N., Morrissey, S.P., Anxionnat, R., Pittion-Vouyovitch, S., Vespignani, H., Edan, G. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis. Mult. Scler., 2004, 10, 407-412.
99. Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., Langer-Gould, A., Smith, C.H., The HERMES Trial Group B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. N. Engl. J. Med., 2008, 358, 676-688.
100. Monson, N.L., Cravens, P.D., Frohman, E.M., Hawker, K., Racke, M.K. Effect of Rituximab on the Peripheral Blood and Cerebrospinal Fluid B Cells in Patients With Primary Progressive Multiple Sclerosis. Arch. Neurol., 2005, 62, 258-264.
101. Cree, B.A.C., Lamb, S., Morgan, K., Chen, A., Waubant, E., Genain, C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology, 2005, 64, 1270-1272.
102. Burt, R.K., Cohen, B.A., Russell, E., Spero, K., Joshi, A., Oyama, Y., Karpus, W.J., Luo, K., Jovanovic, B., Traynor, A., Karlin, K., Stefoski, D., Burns, W.H. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood, 2003, 102, 2373-2378.
103. Eigenbrod, S., Derwand, R., Jakl, V., Endres, S., Eigler, A. Sphingosine Kinase and Sphingosine-1-Phosphate Regulate Migration, Endocytosis and Apoptosis of Dendritic Cells. Immunol. Investig., 2006, 35, 149-165.
104. Cyster, J.G. Chemokines, Sphingosine-1-Phosphate, and cell migration in secondary lymphoid organs. Annu. Rev. Immunol., 2005, 23, 127-159.
105. Kappos, L., Freedman, M.S., Polman, C.H., Edan, G., Hartung, H.-P., Miller, D.H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., Dahms, S., Lanius, V., Pohl, C., Sandbrink, R. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet, 2007, 370, 389-397.
106. Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G.B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., Amato, M.P. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann. Neurol., 2007, 61, 300-306.
107. Kalkers, N.F., Barkhof, F., Bergers, E., van Schijndel, R., Polman, C.H. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler., 2002, 8, 532-533.
108. Yrjanheikki, J., Keinanen, R., Pellikka, M., Hokfelt, T., Koistinaho, J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. USA, 1998, 95, 15769-15774.
109. Giuliani, F., Metz, L.M., Wilson, T., Fan, Y., Bar-Or, A., Wee Yong, V. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol., 2005, 158, 213-221.
110. Basso, A.S., Frenkel, D., Quintana, F.J., Costa-Pinto, F.A., Petrovic-Stojkovic, S., Puckett, L., Monsonego, A., Bar-Shir, A., Engel, Y., Gozin, M., Weiner, H.L. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest., 2008, 118, 1532-1543.
111. Lo, A.C., Black, J.A., Waxman, S.G. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport, 2002, 13, 1909-1912.
112. Bechtold, D.A., Kapoor, R., Smith, K.J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann. Neurol., 2004, 55, 607-616.
113. Friese, M.A., Craner, M.J., Etzensperger, R., Vergo, S., Wemmie, J.A., Welsh, M.J., Vincent, A., Fugger, L. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat. Med., 2007, 13, 1483-1489.
114. Kaneko, S., Wang, J., Kaneko, M., Yiu, G., Hurrell, J.M., Chitnis, T., Khoury, S.J., He, Z. Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J. Neurosci., 2006, 26, 9794-9804.
115. Agnello, D., Bigini, P., Villa, P., Mennini, T., Cerami, A., Brines, M.L., Ghezzi, P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res., 2002, 952, 128-134.
116. Sattler, M.B., Merkler, D., Maier, K., Stadelmann, C., Ehrenreich, H., Bahr, M., Diem, R. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ., 2004, 11(Suppl 2), S181-192.
117. Ehrenreich, H., Fischer, B., Norra, C., Schellenberger, F., Stender, N., Stiefel, M., Siren, A.L., Paulus, W., Nave, K.A., Gold, R., Bartels, C. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain, 2007, 130, 2577-2588.
118. Chang, A., Tourtellotte, W.W., Rudick, R., Trapp, B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med., 2002, 346, 165-173.
119. Kuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., Bruck, W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008, 131, 1749-1758.
120. Han, M.H., Hwang, S.I., Roy, D.B., Lundgren, D.H., Price, J.V., Ousman, S.S., Fernald, G.H., Gerlitz, B., Robinson, W.H., Baranzini, S.E., Grinnell, B.W., Raine, C.S., Sobel, R.A., Han, D.K., Steinman, L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature, 2008, 451, 1076-1081.
121. Mi, S., Miller, R.H., Lee, X., Scott, M.L., Shulag-Morskaya, S., Shao, Z., Chang, J., Thill, G., Levesque, M., Zhang, M., Hession, C., Sah, D., Trapp, B., He, Z., Jung, V., McCoy, J.M., Pepinsky, R.B. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci., 2005,8, 745-751.
122. Mi, S., Miller, R.H., Tang, W., Lee, X., Hu, B., Wu, W., Zhang, Y., Shields, C.B., Miklasz, S., Shea, D., Mason, J., Franklin, R.J., Ji, B., Shao, Z., Chedotal, A., Bernard, F., Roulois, A., Xu, J., Jung, V., Pepinsky, B. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann. Neurol., 2009, 65, 304-315.
123. Hawker, K., O'Connor, P., Freedman, M.S., Calabresi, P.A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., Zhang, J., Chin, P., Smith, C.H. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol., 2009, 66, 460-471.
124. Leary, S.M., Thompson, A.J. Interferon beta-1a in primary progressive multiple sclerosis. J. Neurol. Sci., 2003, 206, 215-216.
125. Loftus, B., Newsom, B., Montgomery, M., Von Gynz-Rekowski, K., Riser, M., Inman, S., Garces, P., Rill, D., Zhang, J., Williams, J.C. Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. Clin. Immunol., 2009, 131, 202-215.
126. Pohlau, D., Przuntek, H., Sailer, M., Bethke, F., Koehler, J., Konig, N., Heesen, C., Spath, P., Andresen, I. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult. Scler., 2007, 13, 1107-1117.
127. Goodman, A.D., Brown, T.R., Krupp, L.B., Schapiro, R.T., Schwid, S.R., Cohen, R., Marinucci, L.N., Blight, A.R. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet, 2009, 373, 732-738.
128. Wiendl, H., Kieseier, B.C., Weissert, R., Mylius, H.A., Pichlmeier, U., Hartung, H.P., Melms, A., Kuker, W., Weller, M. Treatment of active secondary progressive multiple sclerosis with treosulfan. J. Neurol., 2007, 254, 884-889.